OptimizeRx Statistics
Total Valuation
OptimizeRx has a market cap or net worth of $183.98 million. The enterprise value is $205.26 million.
| Market Cap | 183.98M |
| Enterprise Value | 205.26M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, after market close.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OptimizeRx has 18.27 million shares outstanding. The number of shares has increased by 6.29% in one year.
| Shares Outstanding | 18.27M |
| Shares Change (YoY) | +6.29% |
| Shares Change (QoQ) | +2.21% |
| Owned by Insiders (%) | 13.14% |
| Owned by Institutions (%) | 72.73% |
| Float | 14.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 29.15 |
| PS Ratio | 2.35 |
| Forward PS | 1.75 |
| PB Ratio | 1.50 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.61 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.30.
| Current Ratio | 2.88 |
| Quick Ratio | 2.68 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.44 |
Financial Efficiency
Return on equity (ROE) is -15.00% and return on invested capital (ROIC) is -15.33%.
| Return on Equity (ROE) | -15.00% |
| Return on Assets (ROA) | -11.90% |
| Return on Capital (ROIC) | -15.33% |
| Revenue Per Employee | $579,323 |
| Profits Per Employee | -$133,831 |
| Employee Count | 135 |
| Asset Turnover | 0.52 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -7.25M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.08% in the last 52 weeks. The beta is 1.28, so OptimizeRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -29.08% |
| 50-Day Moving Average | 11.04 |
| 200-Day Moving Average | 11.43 |
| Relative Strength Index (RSI) | 34.95 |
| Average Volume (20 Days) | 114,787 |
Short Selling Information
The latest short interest is 1.02 million, so 5.61% of the outstanding shares have been sold short.
| Short Interest | 1.02M |
| Short Previous Month | 1.03M |
| Short % of Shares Out | 5.61% |
| Short % of Float | 7.10% |
| Short Ratio (days to cover) | 6.89 |
Income Statement
In the last 12 months, OptimizeRx had revenue of $78.21 million and -$18.07 million in losses. Loss per share was -$1.03.
| Revenue | 78.21M |
| Gross Profit | 47.67M |
| Operating Income | -24.37M |
| Pretax Income | -25.32M |
| Net Income | -18.07M |
| EBITDA | -19.32M |
| EBIT | -22.32M |
| Loss Per Share | -$1.03 |
Balance Sheet
The company has $15.18 million in cash and $36.46 million in debt, giving a net cash position of -$21.28 million or -$1.16 per share.
| Cash & Cash Equivalents | 15.18M |
| Total Debt | 36.46M |
| Net Cash | -21.28M |
| Net Cash Per Share | -$1.16 |
| Equity (Book Value) | 122.54M |
| Book Value Per Share | 6.71 |
| Working Capital | 31.59M |
Cash Flow
In the last 12 months, operating cash flow was -$5.03 million and capital expenditures -$791,941, giving a free cash flow of -$5.83 million.
| Operating Cash Flow | -5.03M |
| Capital Expenditures | -791,941 |
| Free Cash Flow | -5.83M |
| FCF Per Share | -$0.32 |
Margins
Gross margin is 60.95%, with operating and profit margins of -31.16% and -23.10%.
| Gross Margin | 60.95% |
| Operating Margin | -31.16% |
| Pretax Margin | -32.38% |
| Profit Margin | -23.10% |
| EBITDA Margin | -24.70% |
| EBIT Margin | -28.54% |
| FCF Margin | -7.45% |
Dividends & Yields
OptimizeRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.29% |
| Shareholder Yield | -6.29% |
| Earnings Yield | -9.82% |
| FCF Yield | -3.17% |
Analyst Forecast
The average price target for OptimizeRx is $16.00, which is 58.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.00 |
| Price Target Difference | 58.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 14, 2018. It was a reverse split with a ratio of 1:3.
| Last Split Date | May 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
OptimizeRx has an Altman Z-Score of 1.73 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.73 |
| Piotroski F-Score | 2 |